Investigation of an Omaha cancer researcher uncovered no evidence that he violated federal conflict-of-interest standards, the Department of Health, Education and Welfare announced yesterday.
However, Dr. Philippe Shubik, director of Eppley Cancer Institute and a member of the government's National Cancer Advisory Board, made inaccurate disclosure of fees he was paid as a consultant to General Foods and Procter & Gamble, Inspector General Thomas Morris reported.
HEW forwarded that information to the Justice Department, but Justice has decided not to prosecute, Morris said.
Eppley Institute, part of the University of Nebraska Medical Center, has received $23 million in contracts for cancer research since 1968.
The HEW report said Shubik did not use as influence as a member of the board that advises Hew's National Cancer Institute to secur contracts for Eppley.
But it confirmed an earlier General Accounting Office audit that the National Cancer Institute bypassed routine contracting procedures in awarding grant to Eppley.
The HEW report said: "We have no evidence that Dr. Shubik violated the conflict-of-interest standards. We are troubled, however by the fact, that, whatever his motive, Dr. Shubik's generally pro-industry positions on government advisory groups coincided with the interests of his industrial clients.
"This is another case in which the variety of roles assumed by Dr. Shubki gives, at the minimum, the appearance of impropriety."
The report said Shubik played a role in the board's 1975 decision that chemicals that caused benign, rather than malignant, tumors should not be classified as carcinogens.
Shubik also has testified at Food and Drug Administration and HEW hearings on behalf of corporate clients.